Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 11/20 | 0.41 |
| ▸ | MAP2K2 | P36507 | 9/20 | 0.41 |
| ▸ | FLT1 | P17948 | 7/20 | 0.38 |
| ▸ | KDR | P35968 | 7/20 | 0.38 |
| ▸ | PIM1 | P11309 | 1/20 | 0.36 |
| ▸ | CAMK2B | Q13554 | 1/20 | 0.36 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.35 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6207184 | 0.88 | FLT1 (0.39) | FLT1KDR | |
| SCHEMBL21067809 | 0.87 | MAP2K1 (0.46) | MAP2K1MAP2K2PIM1CAMK2B | |
| SCHEMBL6208327 | 0.85 | MAP2K1 (0.52) | MAP2K1MAP2K2PIM1CAMK2B | |
| SCHEMBL6187892 | 0.85 | MAP2K1 (0.45) | MAP2K1MAP2K2KDRPIM1CAMK2B | |
| SCHEMBL6403618 | 0.85 | MAP2K1 (0.40) | MAP2K1MAP2K2KDRPIM1CAMK2B | |
| SCHEMBL6208074 | 0.85 | MAP2K1 (0.40) | MAP2K1MAP2K2PIM1CAMK2B | |
| SCHEMBL6398520 | 0.85 | PIM1 (0.46) | MAP2K1MAP2K2PIM1CAMK2B | |
| SCHEMBL6406565 | 0.84 | PIM1 (0.39) | MAP2K1MAP2K2FLT1KDRPIM1 | |
| SCHEMBL6399813 | 0.84 | MAP2K1 (0.43) | MAP2K1MAP2K2PIM1CAMK2B | |
| SCHEMBL6187354 | 0.84 | MAP2K1 (0.48) | MAP2K1MAP2K2PIM1CAMK2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050004186-A1 | MEK inhibiting compounds | PFIZER INC | 2005-01-06 | — | — | US | claimed |
| US-20050004186-A1 | MEK inhibiting compounds | PFIZER INC | 2005-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004186-A1 | MEK inhibiting compounds | MAPK1, MAP3K1, MAPK3 | MAP2K1 46/4885MAP2K2 40/4885FLT1 349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.